NGM BIOPHARMACEUTICALS INC: Nasdaq/NYSE listing notice — NGM Biopharmaceuticals receives Nasdaq bid price deficiency notice; stock below $1.00 for 30 days

NGM BIOPHARMACEUTICALS INC

Received Nasdaq notice on Dec 1, 2023; bid price below $1.00 for 30 consecutive business days.
Has until May 29, 2024 (180 days) to regain compliance by closing at $1.00+ for 10 consecutive days.
May transfer to Nasdaq Capital Market for an additional 180-day compliance period if needed.
Company will monitor and consider options, including a potential reverse stock split, to cure deficiency.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

NGM BIOPHARMACEUTICALS INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A)

Exact text from the filing

December 1, 2023, NGM Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), received a letter from the Listing Qualifications Staff (the “Nasdaq Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days, the bid price of the Company’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5450(a)(1). The notification received has no immediate effect on the listing of the Company’s common stock on The Nasdaq Global Select Market. In

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001193125-23-288513

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.